Nutraveris

Category 'INGREDIENTS'

Tuesday, March 19, 2019
Category : NEWS, INGREDIENTS, CLINICAL EVIDENCE | Author : experts | Comment : No Comments
Tags:

NOL, Nutraveris Online, the most efficient data solution to create, keep up-to-date and launch your products in the 28 EU member states, used for 10years by more than 500 industry leaders informs you:

 

Red yeast rice has been suspected to induce some toxicological side effects. The aim of this systematic review and meta-analysis was to examine the available scientific evidences on the safety of red yeast rice supplementations. Data were pooled from 53 randomized and controlled trial, for a total of 8535 subjects (5537 supplemented with red yeast rice and 4303 controls).

Red yeast rice

Results showed that red yeast rice was not associated with increased risk of musculoskeletal disorders (OR = 0.94, 95% CI: 0.53-1.65). In addition, reduced risk of non-skeletal musculoskeletal adverse events (OR = 0.59, 95% CI: 0.50-0.69) and serious adverse events (OR = 0.54, 95% CI: 0.46-0.64) have been measured with red yeast rice in comparison to control. Furthermore, increasing the doses of monacolin K was negatively associated with increasing risk of non-skeletal musculoskeletal adverse events.

 

In conclusion, this large meta-analysis demonstrate that the use of red yeast rice as hypocholesterolemic supplement is not associated with safety concern.

 

 

Fogacci F, Banach M, Mikhailidis DP, Bruckert E, Toth PP, Watts GF, Reiner Ž, Mancini J, Rizzo M, Mitchenko O, Pella D, Fras Z, Sahebkar A, Vrablik M, Cicero AFG; Lipid and Blood Pressure Meta-analysis Collaboration (LBPMC) Group the International Lipid Expert Panel (ILEP). SAFETY OF RED YEAST RICE SUPPLEMENTATION: A SYSTEMATIC REVIEW AND META-ANALYSIS OF RANDOMIZED CONTROLLED TRIALS. Pharmacol Res. 2019 Mar 4. pii: S1043-6618(19)30317-2.

 

This information has been sourced by NOL, a collaborative and complete tool which contains all Regulatory, Scientific and Marketing data

  • It solves all regulatory issues since it contains the required information on all ingredients authorized in the 28 European member states…on regulatory status, health claims, authority opinions
  • It protects your investments since it is updated in real time with reliable quality information analyzed and reviewed by our experts, available hotline.
  • It enables you to be the most responsive with monthly reports and live alerts and a personal use of the information with a report editing tool and customizable bookmarks.

With NOL let’s : 

  • Formulate new innovative products
  • Check if your already existing formulas are still compliant with the in force regulations
  • Adapt your existing formulas to the requirements of other European countries where you are willing to export them
  • Do scientific & regulatory & marketing monitoring which enable to anticipate the withdrawal of products, the safety issues, new interesting scientific studies, the arrival of new players on the market…

 

More information on www.nutraveris.com

Contact our Scientific & Regulatory experts at NUTRAVERIS

contact@nutraveris.com, +33 2 96 76 54 87

Thursday, March 14, 2019
Category : NEWS, INGREDIENTS, CLINICAL EVIDENCE | Author : experts | Comment : No Comments
Tags:

NOL, Nutraveris Online, the most efficient data solution to create, keep up-to-date and launch your products in the 28 EU member states, used for 10years by more than 500 industry leaders informs you:

 

This randomized, double-blind, placebo-controlled trial evaluated the effects of melatonin administration on metabolic status in 60 diabetic patients with coronary heart disease (CHD).

Subjects were allocated into two groups to receive either 10 mg melatonin (2 melatonin capsules, 5 mg each) (n = 30) or placebo (n = 30) once a day for 12 weeks.

 

cardio-metabolic risk

 

Taking melatonin, compared with the placebo, significantly reduced fasting plasma glucose (p = 0.03), serum insulin concentrations (p = 0.008), homeostasis model of assessment-estimated insulin resistance (p = 0.04), total-/HDL-cholesterol ratio (p = 0.02) and systolic (p = 0.01) and diastolic blood pressure (p = 0.04). Melatonin treatment also significantly increased quantitative insulin sensitivity check index (p = 0.01) and serum HDL-cholesterol (p = 0.04).

In addition, compared with the placebo, melatonin supplementation resulted in significant increases in plasma glutathione (p = 0.02) and nitric oxide (p = 0.03), and significant decreases in malondialdehyde (p = 0.007), protein carbonyl (p < 0.001) and serum high sensitivity C-reactive protein levels (p = 0.001).

Overall, melatonin intake for 12 weeks to diabetic patients with CHD had beneficial effects on biomarkers of oxidative stress and cardio-metabolic risk.

 

Raygan F, Ostadmohammadi V, Bahmani F, Reiter RJ, Asemi Z. Melatonin administration lowers biomarkers of oxidative stress and cardio-metabolic risk in type 2 diabetic patients with coronary heart disease: A randomized, double-blind, placebo-controlled trial. Clin Nutr. 2019 Feb;38(1):191-196.

 

This information has been sourced by NOL, a collaborative and complete tool which contains all Regulatory, Scientific and Marketing data

  • It solves all regulatory issues since it contains the required information on all ingredients authorized in the 28 European member states…on regulatory status, health claims, authority opinions
  • It protects your investments since it is updated in real time with reliable quality information analyzed and reviewed by our experts, available hotline.
  • It enables you to be the most responsive with monthly reports and live alerts and a personal use of the information with a report editing tool and customizable bookmarks.

With NOL let’s : 

  • Formulate new innovative products
  • Check if your already existing formulas are still compliant with the in force regulations
  • Adapt your existing formulas to the requirements of other European countries where you are willing to export them
  • Do scientific & regulatory & marketing monitoring which enable to anticipate the withdrawal of products, the safety issues, new interesting scientific studies, the arrival of new players on the market…

 

More information on www.nutraveris.com

Contact our Scientific & Regulatory experts at NUTRAVERIS

contact@nutraveris.com, +33 2 96 76 54 87

Thursday, March 7, 2019
Category : NEWS, INGREDIENTS, CLINICAL EVIDENCE | Author : experts | Comment : No Comments
Tags:

NOL, Nutraveris Online, the most efficient data solution to create, keep up-to-date and launch your products in the 28 EU member states, used for 10years by more than 500 industry leaders informs you:

 

This systematic review and meta-analysis focusses on the effects of resveratrol on obesity measures. 28 clinical trial shave been compiled. Supplementation ranged from 8 to 3000 mg/day of resveratrol (median 300 mg/day) and duration from 4 to 52 weeks (median 12 weeks). The authors included studies conducted in healthy subjects, or patients with type 2 diabetes, nonalcoholic fatty liver disease, metabolic syndrome, overweight/obesity or patients with schizophrenia or Alzheimer’s disease.

resveratrol

Results showed that resveratrol reduced body weight (weighted mean difference (WMD) = -0.51 kg, 95% Ci: -0.94, -0.09, p = 0.02), BMI (WMD = -0.17 kg/m², 95% CI: -0.32, -0.03, p = 0.02) and waist circumference (WMD = -0.79 cm, 95% CI: -1.39, -0.2, p = 0.009). Conversely, no change has been measured on fat mass. Resveratrol was effective in studies assessing the effects of dosage of < 500 mg/day, with long term intervention (> 3 months) or in people with obesity.

 

Therefore, this meta-analysis reports a small but significant effect of resveratrol an anthropometric measures.

 

 

Mousavi SM, Milajerdi A, Sheikhi A, Kord-Varkaneh H, Feinle-Bisset C, Larijani B, Esmaillzadeh A. Resveratrol supplementation significantly influences obesity measures: a systematic review and dose-response meta-analysis of randomized controlled trials. Obes Rev. 2019 Mar;20(3):487-498.

 

This information has been sourced by NOL, a collaborative and complete tool which contains all Regulatory, Scientific and Marketing data

  • It solves all regulatory issues since it contains the required information on all ingredients authorized in the 28 European member states…on regulatory status, health claims, authority opinions
  • It protects your investments since it is updated in real time with reliable quality information analyzed and reviewed by our experts, available hotline.
  • It enables you to be the most responsive with monthly reports and live alerts and a personal use of the information with a report editing tool and customizable bookmarks.

With NOL let’s : 

  • Formulate new innovative products
  • Check if your already existing formulas are still compliant with the in force regulations
  • Adapt your existing formulas to the requirements of other European countries where you are willing to export them
  • Do scientific & regulatory & marketing monitoring which enable to anticipate the withdrawal of products, the safety issues, new interesting scientific studies, the arrival of new players on the market…

 

More information on www.nutraveris.com

Contact our Scientific & Regulatory experts at NUTRAVERIS

contact@nutraveris.com, +33 2 96 76 54 87

Friday, March 1, 2019
Category : NEWS, INGREDIENTS, INNOVATION, CLINICAL EVIDENCE | Author : experts | Comment : No Comments
Tags:

NOL, Nutraveris Online, the most efficient data solution to create, keep up-to-date and launch your products in the 28 EU member states, used for 10years by more than 500 industry leaders informs you:

 

This randomized, open-label, placebo-controlled and crossover study examined the effects of fresh pear consumption (2 pears per day for 12 weeks) in middle-aged/older adults with metabolic syndrome.

The effects of pear was compared to a calorie-matched control drink. Both supplementation periods were separated by a 4-week washout.

pear

After 12 weeks, a trend to decreased in systolic blood pressure (p = 0.07) and a significant decreased in pulse pressure (p < 0.05) has been noted after the pear supplementation. Moreover, leptin concentrations were lower in the pear group than in controls (p < 0.05). In addition, waist circumference was lower after pear supplementation than after the control drink (p < 0.05). Similarly, waist-to-hip ratio was significant lower in the pear group in comparison to control at 6 and 12 weeks (p < 0.05 for both).

 

Therefore, this study suggest that consumption of 2 pears per day can improve the cardiometabolic health and reduce some anthropometric measures in subjects with metabolic syndrome.

 

Navaei N, Pourafshar S, Akhavan NS, Litwin NS, Foley EM, George KS, Hartley SC, Elam ML, Rao S, Arjmandi BH, Johnson SA. Influence of daily fresh pear consumption on biomarkers of cardiometabolic health in middle-aged/older adults with metabolic syndrome: a randomized controlled trial. Food Funct. 2019 Feb 5.

 

This information has been sourced by NOL, a collaborative and complete tool which contains all Regulatory, Scientific and Marketing data

  • It solves all regulatory issues since it contains the required information on all ingredients authorized in the 28 European member states…on regulatory status, health claims, authority opinions
  • It protects your investments since it is updated in real time with reliable quality information analyzed and reviewed by our experts, available hotline.
  • It enables you to be the most responsive with monthly reports and live alerts and a personal use of the information with a report editing tool and customizable bookmarks.

With NOL let’s : 

  • Formulate new innovative products
  • Check if your already existing formulas are still compliant with the in force regulations
  • Adapt your existing formulas to the requirements of other European countries where you are willing to export them
  • Do scientific & regulatory & marketing monitoring which enable to anticipate the withdrawal of products, the safety issues, new interesting scientific studies, the arrival of new players on the market…

 

More information on www.nutraveris.com

Contact our Scientific & Regulatory experts at NUTRAVERIS

contact@nutraveris.com, +33 2 96 76 54 87

Thursday, February 21, 2019
Category : NEWS, INGREDIENTS, INNOVATION, CLINICAL EVIDENCE | Author : experts | Comment : No Comments
Tags:

NOL, Nutraveris Online, the most efficient data solution to create, keep up-to-date and launch your products in the 28 EU member states, used for 10years by more than 500 industry leaders informs you:

 

This meta-analysis was performed with 17 randomized clinical trials and evaluated the effects of omega-3 supplementation among 3363 patients in the management of dry eye disease.

omega-3 supplementation

Compared with placebo, omega-3 fatty acid supplementation decreased dry eye symptoms (p < 0.001) and corneal fluorescein staining (p = 0.032), whereas it increased the breakup time (p < 0.001) and Schirmer test values (used to test the amount of tears) (p < 0.001). No evidence of publication bias was observed, and sensitivity analyses indicated the robustness of results obtained. Meta-regression analysis showed a higher improvement of dry eye symptoms and breakup time in studies conducted in India.

 

In conclusion, this meta-analysis provides evidence that omega-3 fatty acid supplementation significantly improves dry eye symptoms and signs in patients with dry eye disease. 

 

Giannaccare G, Pellegrini M, Sebastiani S, Bernabei F, Roda M, Taroni L, Versura P, Campos EC.Efficacy of Omega-3 Fatty Acid Supplementation for Treatment of Dry Eye Disease: A Meta-Analysis of Randomized Clinical Trials. Cornea. 2019 Jan 29.

 

This information has been sourced by NOL, a collaborative and complete tool which contains all Regulatory, Scientific and Marketing data

  • It solves all regulatory issues since it contains the required information on all ingredients authorized in the 28 European member states…on regulatory status, health claims, authority opinions
  • It protects your investments since it is updated in real time with reliable quality information analyzed and reviewed by our experts, available hotline.
  • It enables you to be the most responsive with monthly reports and live alerts and a personal use of the information with a report editing tool and customizable bookmarks.

With NOL let’s : 

  • Formulate new innovative products
  • Check if your already existing formulas are still compliant with the in force regulations
  • Adapt your existing formulas to the requirements of other European countries where you are willing to export them
  • Do scientific & regulatory & marketing monitoring which enable to anticipate the withdrawal of products, the safety issues, new interesting scientific studies, the arrival of new players on the market…

 

More information on www.nutraveris.com

Contact our Scientific & Regulatory experts at NUTRAVERIS

contact@nutraveris.com, +33 2 96 76 54 87